Volume : 09, Issue : 07, July – 2022



Authors :

Nimma Vijaya Reka, S.K. Godasu, P.Raju , Kyatham Hemanth, Uootukuru Ashwini

Abstract :

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Ixora coccinea was made on the basis of its High therapeutic value. They are mostly shrubs and small trees that are part of the under-storey plant community in the tropical forest. The preliminary phytochemical investigation of powdered Ixora coccinea showed the presence of Carbohydrates, Alkaloids, Glycosides, Steroid, Terpenoids, Flavonoids, Proteins and Amino acids. The pharmacological and acute toxicity studies of ethanolic extract was performed by following, OECD-423 guidelines (Acute toxic class method). No mortality or acute toxicity was observed upto 2000mg/kg of body weight. The Biological dose of extract Ixora coccinea dose was selected 200mg/kg and 400mg/kg in this dose possessed significant antidiabetic activity. Alloxan causes a massive destruction of β-cells of the islets of Langerhans, resulting in reduced synthesis and release of insulin. The function of the insulin suppressed, which leads to high level of hyperglycemic and eventually to death, but the different extracts of Ixora coccinea showed antidiabetic effect in alloxan induced diabetic rats and reduced the mortality rate significantly.
KEY WORDS: Ixora coccinea, Anti-diabetic activity, Leaves, Ethanolic extract

Cite This Article:

Please cite this article in press Nimma Vijaya Reka, et al, Evaluation Of Anti Diabetic Activity Of Ethanolic Extract Of Ixora Coccinea Leaves., Indo Am. J. P. Sci, 2022; 09(7).,

Number of Downloads : 10


1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 Suppl 1:S81–S90. [PubMed] [Google Scholar]
2. Craig ME, Hattersley A, Donaghue KC. Definition, epidemiology and classification of diabetes in children and adolescents. Pediatr Diabetes. 2009;10 Suppl 12:3–12. [PubMed] [Google Scholar]
3. Galtier F. Definition, epidemiology, risk factors. Diabetes Metab. 2010;36:628–651. [PubMed] [Google Scholar]
4. Thunander M, Törn C, Petersson C, Ossiansson B, Fornander J, Landin-Olsson M. Levels of C-peptide, body mass index and age, and their usefulness in classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden. Eur J Endocrinol. 2012;166:1021–1029. [PMC free article] [PubMed] [Google Scholar]
5. Stone MA, Camosso-Stefinovic J, Wilkinson J, de Lusignan S, Hattersley AT, Khunti K. Incorrect and incomplete coding and classification of diabetes: a systematic review. Diabet Med. 2010;27:491–497. [PubMed] [Google Scholar]
6. Rosenbloom AL, Silverstein JH, Amemiya S, Zeitler P, Klingensmith GJ. Type 2 diabetes in children and adolescents. Pediatr Diabetes. 2009;10 Suppl 12:17–32. [PubMed] [Google Scholar]
7. Cakan N, Kizilbash S, Kamat D. Changing spectrum of diabetes mellitus in children: challenges with initial classification. Clin Pediatr (Phila) 2012;51:939–944. [PubMed] [Google Scholar]
8. Wilkin TJ. The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type I as well as type II diabetes. Int J Obes (Lond) 2009;33:716–726. [PubMed] [Google Scholar]
9. Canivell S, Gomis R. Diagnosis and classification of autoimmune diabetes mellitus. Autoimmun Rev. 2014;13:403–407. [PubMed] [Google Scholar]
10. Lamb MM, Yin X, Zerbe GO, Klingensmith GJ, Dabelea D, Fingerlin TE, Rewers M, Norris JM. Height growth velocity, islet autoimmunity and type 1 diabetes development: the Diabetes Autoimmunity Study in the Young. Diabetologia. 2009;52:2064–2071. [PMC free article] [PubMed] [Google Scholar]
11. Vehik K, Hamman RF, Lezotte D, Norris JM, Klingensmith GJ, Dabelea D. Childhood growth and age at diagnosis with Type 1 diabetes in Colorado young people. Diabet Med. 2009;26:961–967. [PubMed] [Google Scholar]
12. Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS; DPT-1 Study Group. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes. 2010;59:679–685. [PMC free article] [PubMed] [Google Scholar]
13. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes. 2003;52:581–587. [PubMed] [Google Scholar]
14. Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev. 2004;25:612–628. [PubMed] [Google Scholar]
15. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996;19:257–267. [PubMed] [Google Scholar]
16. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–1070. [PMC free article] [PubMed] [Google Scholar]
17. Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012;30:49–59. [PubMed] [Google Scholar]
18. Halban PA, Polonsky KS, Bowden DW, Hawkins MA, Ling C, Mather KJ, Powers AC, Rhodes CJ, Sussel L, Weir GC. β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care. 2014;37:1751–1758. [PMC free article] [PubMed] [Google Scholar]
19. Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol. 2005;4:5. [PMC free article] [PubMed] [Google Scholar]
20. Kaneto H, Kajimoto Y, Miyagawa J, Matsuoka T, Fujitani Y, Umayahara Y, Hanafusa T, Matsuzawa Y, Yamasaki Y, Hori M. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. Diabetes. 1999;48:2398–2406. [PubMed] [Google Scholar]
21. Nebbioso M, Federici M, Rusciano D, Evangelista M, Pescosolido N. Oxidative stress in preretinopathic diabetes subjects and antioxidants. Diabetes Technol Ther. 2012;14:257–263. [PubMed] [Google Scholar]
22. Kilic G, Alvarez-Mercado AI, Zarrouki B, Opland D, Liew CW, Alonso LC, Myers MG, Jonas JC, Poitout V, Kulkarni RN, et al. The islet estrogen receptor-α is induced by hyperglycemia and protects against oxidative stress-induced insulin-deficient diabetes. PLoS One. 2014;9:e87941. [PMC free article] [PubMed] [Google Scholar]